BRIEF published on 04/28/2026 at 20:40, 1 month 29 days ago GenSight Biologics announces its 2026 Combined General Meeting Shareholders Gene Therapy General Assembly Preparatory Documents GenSight Biologics
BRIEF published on 04/28/2026 at 20:40, 1 month 29 days ago GenSight Biologics Schedules Annual General Meeting for May 2026 Annual General Meeting Regulatory Compliance Shareholder Information Investor Relations Gene Therapy
PRESS RELEASE published on 04/28/2026 at 20:35, 1 month 29 days ago Inside Information / Other news releases GenSight Biologics to hold Annual General Meeting on May 19, 2026, in Paris. Shareholders can access preparatory documents online. Meeting details and documents available on company website Annual General Meeting Shareholders Preparatory Documents Meeting Details GenSight Biologics
BRIEF published on 04/07/2026 at 19:04, 2 months 20 days ago GenSight Biologics Reports Cash Status and Early Access Revenues Revenue Cash Position Gene Therapy GenSight Biologics Early Access Program
BRIEF published on 04/07/2026 at 19:04, 2 months 20 days ago GenSight Biologics: Financial Update and Progress on AAC Fundraising Treasury Gene Therapy GenSight Biologics Compassionate Access
PRESS RELEASE published on 04/07/2026 at 18:59, 2 months 20 days ago Inside Information / News release on accounts, results GenSight Biologics reports cash position and revenue from early access program as of March 31, 2026. Operating cash burn, fundraising, and treatment proceeds highlighted Revenue Fundraising Cash Position GenSight Biologics Early Access Program
BRIEF published on 03/27/2026 at 07:35, 3 months ago GenSight Biologics Reports 2025 Financial Performance Financing Activities Cash Runway R&D Expenses Regulatory Milestones Financial Results 2025
PRESS RELEASE published on 03/27/2026 at 07:30, 3 months ago Inside Information / News release on accounts, results GenSight Biologics reported estimated full-year consolidated financial results for 2025, highlighting key regulatory milestones achieved and cash runway projection through December 2026 Financial Results Phase III Trial GenSight Biologics Cash Runway Regulatory Milestones
BRIEF published on 03/23/2026 at 09:53, 3 months 4 days ago Heights Capital Management exceeds 8% of GENSIGHT BIOLOGICS' capital Capital Increase Threshold Crossing GenSight Biologics Capital And Voting Rights Heights Capital
BRIEF published on 03/18/2026 at 10:20, 3 months 9 days ago GenSight Biologics finalizes its €1.7 million fundraising round Ordinary Shares Fundraising GenSight Biologics Gene Therapies Risk Factors
Published on 06/27/2026 at 16:50, 7 hours 16 minutes ago Redwood AI Announces Definitive Agreement with Quantum.IQ and Expands into Quantum Resistant Cyber Security
Published on 06/27/2026 at 01:40, 22 hours 26 minutes ago Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 1 day ago Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 1 day 1 hour ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 1 day 1 hour ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/27/2026 at 00:05, 1 day ago EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 1 day ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 1 day ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 1 day ago EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 1 day ago EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE
Published on 06/26/2026 at 07:00, 1 day 17 hours ago Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/25/2026 at 07:30, 2 days 16 hours ago Gimv signs an agreement to acquire Groupe Cap Vert, France’s leading multi-specialist provider of tree and vegetation critical management services, from Ambienta.
